Home Categories API CetrorelixAcetate
M0850535

CetrorelixAcetate , 98% , 120287-85-6

Synonym(s):
Cetrotide;N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N5-(aminocarbonyl)-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide acetic acid salt;NS-75A;SB-75

CAS NO.:120287-85-6

Empirical Formula: C70H92ClN17O14

Molecular Weight: 1431.04

MDL number: MFCD00884467

EINECS: 686-384-6

Pack Size Price Stock Quantity
1mg RMB158.40 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Melting point: >259°C (dec.)
Density  1.42±0.1 g/cm3(Predicted)
storage temp.  Refrigerator
solubility  DMSO (Slightly, Heated), Methanol (Very Slightly)
form  Solid
pka 9.82±0.15(Predicted)
color  White to Off-White
InChIKey SBNPWPIBESPSIF-MHWMIDJBSA-N

Description and Uses

Cetrorelix was launched in Germany for the treatment of female infertility. It is a decapeptidic analog of luteinizing hormone-releasing hormone (LH-RH) bearing structural modifications in the crucial positions 1, 2, 3, 6 and 10 : [Ac-D-Nal1, D-4-CI Phe-2, D-Pal3, D-Cit6, D-Alal0]-GnRH. Cetrorelix is an extremely potent and long acting gonadotrophin releasing hormone (GnRH) antagonist and thus blocks gonadotrophins and sex steroid secretion immediately after administration. Moreover, it has a low histamine-releasing potency. Cetrorelix will be the first LH-RH antagonist approved worldwide. In several Phase III clinical trials, female patients receiving Cetrorelix had a successful controlled ovulation thus avoiding a premature LH-surge. Cetrorelix could be a first-choice in-vitro fertilization (IVF) treatment without the complications of current controlled ovarian hyperstimulation protocols. Cetrorelix is currently under clinical investigation for the treatment of diverse sex hormone dependent disorders such as benign prostate hypertrophy, breast, ovarian or prostate cancers and diverse gynaecological disorders.

Cetrorelix Acetate is an gonadotropin-releasing hormone antagonist and is used to treat hormone-sensitive cancers of the prostate and breast.

Safety

Symbol(GHS) 
GHS08
Signal word  Danger
Hazard statements  H360
Hazardous Substances Data 120287-85-6(Hazardous Substances Data)

RELATED PRODUCTS